ROQ vs. OKYO, OBI, SBTX, AOR, HEMO, NSCI, RLM, BVX, SNG, and CIZ
Should you be buying Roquefort Therapeutics stock or one of its competitors? The main competitors of Roquefort Therapeutics include OKYO Pharma (OKYO), Ondine Biomedical (OBI), SkinBioTherapeutics (SBTX), AorTech International (AOR), Hemogenyx Pharmaceuticals (HEMO), NetScientific (NSCI), Realm Therapeutics (RLM), BiVictriX Therapeutics (BVX), Synairgen (SNG), and Cizzle Biotechnology (CIZ). These companies are all part of the "biotechnology" industry.
Roquefort Therapeutics (LON:ROQ) and OKYO Pharma (LON:OKYO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, community ranking, media sentiment, analyst recommendations, institutional ownership and risk.
Roquefort Therapeutics has higher revenue and earnings than OKYO Pharma. Roquefort Therapeutics is trading at a lower price-to-earnings ratio than OKYO Pharma, indicating that it is currently the more affordable of the two stocks.
Roquefort Therapeutics' return on equity of -27.46% beat OKYO Pharma's return on equity.
OKYO Pharma received 7 more outperform votes than Roquefort Therapeutics when rated by MarketBeat users.
1.7% of Roquefort Therapeutics shares are held by institutional investors. 60.4% of Roquefort Therapeutics shares are held by insiders. Comparatively, 31.9% of OKYO Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
In the previous week, Roquefort Therapeutics and Roquefort Therapeutics both had 1 articles in the media. Roquefort Therapeutics' average media sentiment score of 0.00 equaled OKYO Pharma'saverage media sentiment score.
Roquefort Therapeutics has a beta of 0.05, indicating that its stock price is 95% less volatile than the S&P 500. Comparatively, OKYO Pharma has a beta of -0.06, indicating that its stock price is 106% less volatile than the S&P 500.
Summary
Roquefort Therapeutics beats OKYO Pharma on 7 of the 9 factors compared between the two stocks.
Get Roquefort Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ROQ and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ROQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Roquefort Therapeutics Competitors List
Related Companies and Tools
